11.13
price up icon0.27%   0.03
after-market Dopo l'orario di chiusura: 11.20 0.07 +0.63%
loading
Precedente Chiudi:
$11.10
Aprire:
$11.14
Volume 24 ore:
10.29M
Relative Volume:
2.12
Capitalizzazione di mercato:
$992.16M
Reddito:
$20.65M
Utile/perdita netta:
$-192.65M
Rapporto P/E:
-4.2973
EPS:
-2.59
Flusso di cassa netto:
$-134.39M
1 W Prestazione:
+1.64%
1M Prestazione:
-0.36%
6M Prestazione:
+40.71%
1 anno Prestazione:
+57.20%
Intervallo 1D:
Value
$11.10
$11.25
Intervallo di 1 settimana:
Value
$10.90
$11.25
Portata 52W:
Value
$2.8647
$11.40

Verve Therapeutics Inc Stock (VERV) Company Profile

Name
Nome
Verve Therapeutics Inc
Name
Telefono
(978) 501-3026
Name
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Name
Dipendente
274
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
VERV's Discussions on Twitter

Confronta VERV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VERV
Verve Therapeutics Inc
11.13 989.58M 20.65M -192.65M -134.39M -2.59
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-15 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2024-04-08 Iniziato H.C. Wainwright Buy
2023-04-13 Iniziato Canaccord Genuity Buy
2023-02-01 Iniziato Cantor Fitzgerald Neutral
2022-12-15 Iniziato Goldman Sell
2022-10-06 Iniziato Credit Suisse Neutral
2022-08-25 Aggiornamento Stifel Hold → Buy
2022-06-17 Iniziato BMO Capital Markets Outperform
2022-02-18 Iniziato RBC Capital Mkts Outperform
2021-09-24 Iniziato Stifel Hold
2021-07-12 Iniziato Guggenheim Buy
2021-07-12 Iniziato JP Morgan Neutral
2021-07-12 Iniziato Jefferies Buy
2021-07-12 Iniziato William Blair Outperform
Mostra tutto

Verve Therapeutics Inc Borsa (VERV) Ultime notizie

pulisher
Jul 24, 2025

Lilly completes tender offer for Verve Therapeutics shares - Investing.com

Jul 24, 2025
pulisher
Jul 24, 2025

Lilly and Verve announce expiration of Verve tender offer | Eli Lilly and Company - Eli Lilly

Jul 24, 2025
pulisher
Jul 24, 2025

Lilly Secures 55.7% of Verve Shares in $10.50 Cash Plus CVR Deal, Closing Set for July 25 - Stock Titan

Jul 24, 2025
pulisher
Jul 23, 2025

Verve Therapeutics Inc. Stock Analysis and ForecastRapid portfolio appreciation - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition - MSN

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Verve Therapeutics Inc. stock priceBreakthrough wealth creation - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B - MSN

Jul 22, 2025
pulisher
Jul 22, 2025

Eli Lilly, Verve Therapeutics receive early termination from US FTC - MLex

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Verve Therapeutics Inc. stockHigh-yield investments - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Verve Therapeutics Inc. a good long term investmentPhenomenal trading returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

(VERV) Trading Advice - news.stocktradersdaily.com

Jul 22, 2025
pulisher
Jul 21, 2025

3 Bullish Biotech Stocks With Explosive Growth Trends - MarketBeat

Jul 21, 2025
pulisher
Jul 19, 2025

Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com

Jul 19, 2025
pulisher
Jul 19, 2025

Is Verve Therapeutics Inc. stock a good hedge against inflationFree AI-Driven Trading Strategies - beatles.ru

Jul 19, 2025
pulisher
Jul 16, 2025

Lilly’s $1 billion CRISPR bet: what Verve means for gene editing - The Pharma Letter

Jul 16, 2025
pulisher
Jul 15, 2025

Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360

Jul 15, 2025
pulisher
Jul 15, 2025

Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

Verve Therapeutics Announces Retention Bonus Program for Executives - TipRanks

Jul 15, 2025
pulisher
Jul 14, 2025

Why Verve Therapeutics Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru

Jul 14, 2025
pulisher
Jul 13, 2025

Verve Therapeutics, Inc. (VERV): A Bull Case Theory - MSN

Jul 13, 2025
pulisher
Jul 07, 2025

Prime Medicine soars as Jones sees it as an acquisition target - Seeking Alpha

Jul 07, 2025
pulisher
Jul 06, 2025

Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - MSN

Jul 06, 2025
pulisher
Jun 27, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Jun 27, 2025
pulisher
Jun 27, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (NasdaqVERV), Sage Therapeutics, Inc. (NasdaqSAGE), Cantaloupe, Inc. (NasdaqCTLP), Volato Group, Inc. (NYSE American - Morningstar

Jun 27, 2025
pulisher
Jun 24, 2025

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - MSN

Jun 24, 2025
pulisher
Jun 23, 2025

Lilly To Acquire Verve For One-Time Cardiovascular Treatments - Insider Monkey

Jun 23, 2025
pulisher
Jun 20, 2025

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week - AOL.com

Jun 20, 2025
pulisher
Jun 19, 2025

What is the Intent Behind Eli Lilly's Recent M&A Deals Spree? - Yahoo Finance

Jun 19, 2025
pulisher
Jun 18, 2025

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc.VERV - Business Wire

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics Stock Price, Quotes and Forecasts - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly Acquires Verve Therapeutics In $1.3 Billion Deal - Finimize

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Lilly to acquire Verve Therapeutics for $1.3 billion - C&EN

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks

Jun 18, 2025

Verve Therapeutics Inc Azioni (VERV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):